Generic versions of the Takeda’s (NYSE:TAK) ADHD drug Adderall (amphetamine and dextroamphetamine) remain in short supply after some manufacturers predicted in September that supplies of the drug would stabilize. Experts remain that patients who have experienced trouble getting prescriptions filled switch to other similar amphetamine-based medications, according to The Washington Post. Teva (NYSE:TEVA) recently disclosed…
U.S. Adderall shortage continues
Demand for the attention-deficit/hyperactivity disorder drug Adderall (mixed amphetamine salts) has skyrocketed in the past decade. In 2021, physicians prescribed the medication and its generic equivalents 41.4 million times. Supplies of generic Adderall XR, however, remain scarce. Amneal Pharmaceuticals, Rhodes Pharmaceuticals, Par Pharmaceutical, Sandoz and Teva had the drug on backorder in late August, according…